Norclozapine

Drug Profile

Norclozapine

Alternative Names: N-Desmethylclozapine; ACP-104

Latest Information Update: 18 Jun 2008

Price : $50

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Antipsychotics; Dibenzazepines; Nootropics; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Muscarinic M1 receptor agonists; Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 16 Jun 2008 Discontinued - Phase-II for Schizophrenia in USA (PO)
  • 16 Jun 2008 Interim efficacy data from a phase IIb trial in Schizophrenia released by ACADIA Pharmaceuticals
  • 15 Dec 2007 ACADIA Pharmaceuticals completes enrolment in its phase IIb trial for Schziophrenia in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top